New drug THB335 tested in healthy volunteers for safety
NCT ID NCT06425861
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new drug called THB335 in 60 healthy adults. Participants received either the drug or a placebo in single or multiple doses, and researchers monitored side effects and how the drug moved through the body. Since this is a Phase 1 study in healthy people, there is no direct treatment benefit; the goal is to gather safety and dosing information for future research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- THB335
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
60 people
The number who actually took part.
- Started
-
May 2024
- Finished
-
Dec 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * In good health, determined by no clinically significant findings from medical history, 12 lead electrocardiogram (ECG), vital sign measurements, and clinical laboratory evaluations * Males or females, of any race, between 18 and 65 years of age, inclusive. * Participants must understand the nature of the study and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any study related procedures * Body weight of ≥ 50.0 kg for men and ≥ 45.0 kg for women and Body Mass Index (BMI) of 17.5-32.0 kg/m2 (inclusive) at Screening Exclusion Criteria: * Significant history or clinical manifestation of cancer or any metabolic, allergic, dermatological, hepatic, biliary, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder * Vaccinated within 14 days prior to Day -1 or intention to receive vaccination during the study * A positive urine drug screen/alcohol breath test * The participant currently smokes, vapes, or uses nicotine-containing products.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
QPS Miami
Miami, Florida, 33143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The effects of external nasal dilator strips on sleep and cardiovascular health
- A pharmacokinetic study of NTI164 in healthy adult volunteers
- Genetic determinants of Exercise-Induced muscle damage (POLYGENDOMUS) / déterminants génétiques des dommages musculaires induits par l'Exercice (POLYGENDOMUS)
- Can a simple injection timing reduce bleeding after skin cancer surgery?
- Can Land-Based teachings shape psychedelic therapy training?
- Can a new oral drug pass early safety tests?